Antimicrobials · Antimycobacterials
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
Rifampin functions by inhibiting DNA-dependent RNA polymerase, effectively blocking bacterial RNA synthesis.
The most common benign side effect is orange-red discoloration of body fluids, including urine, sweat, and tears.
Rifampin is a potent inducer of cytochrome P450 enzymes, leading to significant drug-drug interactions and decreased efficacy of medications like oral contraceptives and warfarin.
Monotherapy with rifampin is strictly avoided due to the rapid development of bacterial resistance via mutations in the rpoB gene.
Rifampin is the drug of choice for prophylaxis of close contacts exposed to Neisseria meningitidis or Haemophilus influenzae type b.
Hepatotoxicity, manifesting as elevated transaminases or drug-induced hepatitis, is a serious adverse effect requiring monitoring.
Rifampin is a cornerstone of tuberculosis treatment, specifically used in the RIPE (Rifampin, Isoniazid, Pyrazinamide, Ethambutol) regimen.
Vignette unlocked
A 32-year-old male is brought to the clinic after his roommate was diagnosed with meningococcal meningitis. The patient is asymptomatic and has no significant past medical history. He is currently taking oral contraceptive pills for gender-affirming therapy and warfarin for a history of DVT. The physician decides to initiate chemoprophylaxis to prevent secondary infection. The patient is warned that his urine and sweat may turn orange-red during the course of treatment.
Which of the following is the most important clinical consideration regarding the patient's current medications when prescribing this prophylactic agent?
Decreased efficacy of oral contraceptives and warfarin due to cytochrome P450 induction.
The vignette tests the knowledge that rifampin is a potent CYP450 inducer, which necessitates dose adjustments or alternative strategies for patients on narrow-therapeutic-index drugs like warfarin or hormonal contraceptives.
Full handout
High yield triage
Classification
Rifamycin antibiotic; bactericidal inhibitor of bacterial RNA synthesis.
Indications
Tuberculosis (active/latent), meningococcal prophylaxis, and Staphylococcal prosthetic device infections.
Mechanism of Action
Inhibits DNA-dependent RNA polymerase; prevents transcription.
Side Effects
Orange-red discoloration of body fluids; hepatotoxicity; CYP450 induction.
Contraindications / Monitoring
Concurrent protease inhibitors; monitor LFTs and CBC.
Full handout
Mechanism of Action
Rifampin binds to the beta-subunit of bacterial DNA-dependent RNA polymerase. This binding blocks the elongation of mRNA, effectively halting protein synthesis. It is highly effective against intracellular organisms due to excellent tissue penetration.
Unique Properties
Rifampin is a potent CYP450 inducer, significantly decreasing the serum concentration of many drugs. It is uniquely known for causing orange-red discoloration of urine, sweat, and tears, which is benign but requires patient counseling.
Indications
It is a cornerstone of Tuberculosis therapy (RIPE regimen). It is the drug of choice for meningococcal prophylaxis in close contacts of patients with Neisseria meningitidis. It is also used as an adjunct in Staphylococcal prosthetic valve endocarditis to penetrate biofilms.
Pharmacokinetics
Metabolized primarily by the liver and excreted in bile. It undergoes significant enterohepatic circulation. Due to its role as a potent CYP450 inducer, it accelerates the metabolism of oral contraceptives, warfarin, and HIV medications.
Side Effects & Adverse Events
Common effects include orange-red discoloration of body fluids and GI upset. Hepatotoxicity is a major concern, manifesting as elevated transaminases or clinical hepatitis. Hypersensitivity reactions, including flu-like symptoms, can occur with intermittent dosing.
Contraindications
Concurrent use of protease inhibitors is contraindicated due to massive reduction in drug efficacy. Use with extreme caution in patients with pre-existing liver disease or alcoholism due to the risk of drug-induced hepatitis.
Monitoring
Baseline and periodic LFTs are mandatory to screen for drug-induced injury. Monitor CBC for potential thrombocytopenia or leukopenia. Patients should be warned about the benign orange-red discoloration to prevent unnecessary anxiety.
Clinical Pearls
Always suspect a drug interaction if a patient on Rifampin experiences therapeutic failure of other medications (e.g., breakthrough bleeding on OCPs). Remember it as the first-line agent for meningococcal prophylaxis in exposed contacts.